AC Immune Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3.57	27.31	14.8	3.94	-
Revenue Growth (YoY)	-86.92%	84.51%	276.14%	-	-
Gross Profit	3.57	27.31	14.8	3.94	-
Selling, General & Admin	16.09	17.26	15.31	15.79	17.91
Research & Development	56.44	62.57	54.61	60.34	62.28
Other Operating Expenses	0.55	0.14	1.49	1.34	1.18
Total Operating Expenses	73.08	79.97	71.4	77.47	81.37
Operating Income	-69.51	-52.66	-56.6	-73.53	-81.37
Interest Income	1.87	3.2	1.04	0.07	6.49
Interest Expense	-0.19	-0.13	-0.18	-0.36	-0.58
Other Non-Operating Income (Expense)	-1.13	1.47	-0.6	0.11	6.02
Total Non-Operating Income (Expense)	0.55	4.53	0.27	-0.18	11.92
Pretax Income	-70.45	-50.91	-54.22	-70.74	-72.99
Provision for Income Taxes	-	0	0.01	0.01	0
Net Income	-70.45	-50.92	-54.23	-70.75	-73
Net Income to Common	-70.45	-50.92	-54.23	-70.75	-73
Shares Outstanding (Basic)	101	100	85	84	75
Shares Outstanding (Diluted)	101	100	85	84	75
Shares Change (YoY)	1.06%	17.71%	1.36%	11.48%	4.24%
EPS (Basic)	-0.70	-0.51	-0.64	-0.85	-0.97
EPS (Diluted)	-0.70	-0.51	-0.64	-0.85	-0.97
Shares Outstanding	101.74	100.41	99.2	83.62	83.48
Free Cash Flow	-70.16	65.27	-61.21	-74.81	-68.32
Free Cash Flow Per Share	-0.70	0.65	-0.72	-0.90	-0.91
Gross Margin	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-1945.31%	-192.84%	-382.38%	-1868.69%	-
Profit Margin	-1971.65%	-186.44%	-366.41%	-1798.04%	-
FCF Margin	-1963.67%	238.99%	-413.55%	-1901.07%	-
EBITDA	-67	-50.5	-54.38	-71.17	-78.97
EBITDA Margin	-1875.26%	-184.92%	-367.41%	-1808.74%	-
EBIT	-69.51	-52.66	-56.6	-73.53	-81.37
EBIT Margin	-1945.31%	-192.84%	-382.38%	-1868.69%	-
Effective Tax Rate	0.00%	-0.01%	-0.02%	-0.02%	-0.00%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q